Drug resistance | Total (n=7966) | Subgroups (group 1–4) | P value | |||||
G1: smoker+non-drinker (n=660) | G2: non-smoker+drinker (n=311) | G3: smoker+drinker (n=1316) | G0: non-smoker+non-drinker (n=5709) | G1 vs G0 | G2 vs G0 | G3 vs G0 | ||
DR-TB | 1495 (18.77%) | 127 (19.24%) | 51 (16.4%) | 228 (17.33%) | 1089 (19.08%) | 0.918 | 0.241 | 0.143 |
Any resistance to first-line drug | ||||||||
INH | 820 (10.29%) | 74 (11.21%) | 29 (9.32%) | 123 (9.35%) | 594 (10.40%) | 0.522 | 0.543 | 0.253 |
RIF | 389 (4.88%) | 30 (4.55%) | 12 (3.86%) | 50 (3.80%) | 297 (5.20%) | 0.469 | 0.296 | 0.034* |
EMB | 145 (1.82%) | 11 (1.67%) | 4 (1.29%) | 18 (1.37%) | 112 (1.96%) | 0.602 | 0.526 | 0.149 |
SM | 1050 (13.18%) | 88 (13.33%) | 38 (12.22%) | 152 (11.55%) | 772 (13.52%) | 0.893 | 0.512 | 0.056 |
MR-TB (total) | 891 (11.19%) | 76 (11.52%) | 27 (8.68%) | 144 (10.94%) | 664 (11.63%) | 0.93 | 0.112 | 0.480 |
INH | 266 (3.34%) | 26 (3.94%) | 7 (2.25%) | 42 (3.19%) | 191 (3.35%) | 0.426 | 0.292 | 0.778 |
RIF | 70 (0.88%) | 7 (1.06%) | 3 (0.96%) | 9 (0.68%) | 51 (0.89%) | 0.668 | 0.757 | 0.457 |
EMB | 20 (0.25%) | 1 (0.15%) | 0 (0.00%) | 5 (0.38%) | 20 (0.35%) | 0.717 | 0.622 | 0.871 |
SM | 530 (6.65%) | 41 (6.21%) | 15 (4.82%) | 87 (6.61%) | 387 (6.78%) | 0.582 | 0.179 | 0.827 |
Others | 5 (0.06%) | 1 (0.15%) | 2 (0.64%) | 1 (0.08%) | 1 (0.02%) | 0.197 | 0.008† | 0.340 |
MDR-TB (total) | 276 (3.46%) | 20 (3.03%) | 8 (2.57%) | 39 (2.96%) | 209 (3.66%) | 0.41 | 0.316 | 0.217 |
MDR1:INH+RIF | 58 (0.73%) | 3 (0.45%) | 1 (0.32%) | 17 (1.29%) | 37 (0.65%) | 0.794 | 0.721 | 0.016* |
MDR2:INH+RIF+EMB+SM | 59 (0.74%) | 6 (0.91%) | 3 (0.96%) | 5 (0.38%) | 45 (0.79%) | 0.742 | 0.737 | 0.112 |
MDR3:INH+RIF+SM | 110 (1.38%) | 10 (1.52%) | 3 (0.96%) | 8 (0.61%) | 89 (1.56%) | 0.931 | 0.631 | 0.008† |
Others | 49 (0.62%) | 1 (0.15%) | 1 (0.32%) | 9 (0.68%) | 38 (0.67%) | 0.179 | 0.721 | 0.942 |
PDR-TB (total) | 323 (4.05%) | 31 (4.70%) | 15 (4.82%) | 44 (3.34%) | 233 (4.08%) | 0.452 | 0.521 | 0.215 |
PDR1:INH+EMB | 9 (0.11%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 9 (0.16%) | 0.611 | 1.000 | 0.224 |
PDR2:INH+SM | 257 (3.23%) | 26 (3.94%) | 14 (4.50%) | 41 (3.12%) | 176 (3.08%) | 0.235 | 0.163 | 0.951 |
PDR3:RIF+SM | 32 (0.40%) | 1 (0.15%) | 1 (0.32%) | 2 (0.15%) | 28 (0.49%) | 0.357 | 1.000 | 0.102 |
PDR4:INH+EMB+SM | 9 (0.11%) | 2 (0.30%) | 0 (0.00%) | 0 (0.00%) | 7 (0.12%) | 0.238 | 1.000 | 0.361 |
Others | 16 (0.20%) | 2 (0.30%) | 0 (0.00%) | 1 (0.08%) | 13 (0.23%) | 0.664 | 1.000 | 0.490 |
*p<0.05.
†p<0.01.
DR-TB, drug-resistant TB; EMB, ethambutol; INH, isoniazid; MDR-TB, multidrug resistant TB; MR-TB, mono-resistant TB; PDR-TB, polydrug resistant TB; RIF, rifampin; SM, streptomycin; TB, tuberculosis.